Akita University and Tohoku University present new CTNNB1 and NF-κB activation inhibitors
Oct. 5, 2022
Akita University and Tohoku University have described curcumin derivatives acting as β-catenin (CTNNB1) and NF-κB activation inhibitors reported to be useful for the treatment of cancer.
